Complete searchable index of every FDA and EMA-approved oncology therapy documented across all 50 tumor types on CancerDrugEvidence. Search the table below, or browse by cancer type.
Select a tumor type to view approved therapies, clinical trials, and pipeline data
Filter by name, tumor type, or drug class
| Brand Name | Generic Name | Drug Class | Tumor Types | FDA Year |
|---|---|---|---|---|
| idecabtagene vicleucel (ide-cel) | Multiple Myeloma | Cell Therapy | β | |
| nab-paclitaxel (albumin-bound paclitaxel) | Pancreatic Cancer | Chemotherapy | β | |
| brentuximab vedotin | Hodgkins Lymphoma β’ Mycosis Fungoides | ADC | 2011 | |
| everolimus | Breast Cancer β’ Kidney Cancer β’ Neuroendocrine Tumors | mTOR Inhibitor | 2012 | |
| niraparib + abiraterone acetate | Prostate Cancer | PARP Inhibitor | 2023 | |
| alectinib | Lung Cancer | ALK Inhibitor | β | |
| pemetrexed | Mesothelioma | Chemotherapy | 2004 | |
| brigatinib | Lung Cancer | ALK Inhibitor | β | |
| lifileucel | Melanoma | Cell Therapy | 2024 | |
| nelarabine | Acute Lymphoblastic Leukemia | Chemotherapy | 2005 | |
| atezolizumab + bevacizumab | Liver Cancer | Checkpoint Inhibitor | β | |
| bevacizumab | Brain Cancer β’ Cervical Cancer β’ Colorectal Cancer β’ Lung Cancer β’ Mesothelioma β’ Ovarian Cancer | VEGF/TKI | 2009 | |
| iobenguane i-131 | Pheochromocytoma Paraganglioma | Radiopharmaceutical | β | |
| erdafitinib | Bladder Cancer | Kinase Inhibitor | β | |
| avelumab | Bladder Cancer β’ Merkel Cell Carcinoma | Checkpoint Inhibitor | β | |
| avelumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | 2019 | |
| cisplatin + etoposide + bleomycin | Testicular Cancer | Chemotherapy | β | |
| inotuzumab ozogamicin | Acute Lymphoblastic Leukemia | ADC | β | |
| zenocutuzumab-zbco | Lung Cancer | Bispecific | β | |
| blinatumomab | Acute Lymphoblastic Leukemia | Bispecific | β | |
| bosutinib | Chronic Myeloid Leukemia | BCR-ABL TKI | β | |
| encorafenib + binimetinib | Colorectal Cancer β’ Melanoma | BRAF/MEK | 2017 | |
| lisocabtagene maraleucel | Non Hodgkins Lymphoma | Cell Therapy | 2021 | |
| zanubrutinib | Chronic Lymphocytic Leukemia β’ Mantle Cell Lymphoma β’ Waldenstrom Macroglobulinemia | BTK Inhibitor | 2023 | |
| cabozantinib | Kidney Cancer β’ Liver Cancer β’ Thyroid Cancer | VEGF/TKI | 2021 | |
| liposomal doxorubicin | Kaposi Sarcoma | Chemotherapy | β | |
| acalabrutinib | Chronic Lymphocytic Leukemia β’ Mantle Cell Lymphoma | BTK Inhibitor | 2019 | |
| vandetanib | Thyroid Cancer | RET/Multi-Kinase | 2011 | |
| carboplatin | Testicular Cancer | Chemotherapy | β | |
| ciltacabtagene autoleucel (cilta-cel) | Multiple Myeloma | Cell Therapy | β | |
| lomustine | Brain Cancer | Chemotherapy | β | |
| lomustine (ccnu) | Brain Cancer | Chemotherapy | 1976 | |
| cisplatin + gemcitabine | Nasopharyngeal Carcinoma | Chemotherapy | β | |
| glofitamab-gxbm | Non Hodgkins Lymphoma | Bispecific | 2023 | |
| cobimetinib | Melanoma | BRAF/MEK | 2015 | |
| cyclophosphamide + vincristine + dacarbazine | Pheochromocytoma Paraganglioma | Chemotherapy | β | |
| ramucirumab | Colorectal Cancer β’ Gastric Cancer β’ Liver Cancer β’ Lung Cancer | VEGF/TKI | 2015 | |
| dabrafenib + trametinib | Melanoma | BRAF/MEK | β | |
| daratumumab | Multiple Myeloma | Anti-CD38/SLAMF7 | β | |
| datopotamab deruxtecan | Lung Cancer | ADC | β | |
| glasdegib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2018 | |
| mirvetuximab soravtansine-gynx | Ovarian Cancer | ADC | β | |
| elranatamab-bcmm | Multiple Myeloma | Bispecific | 2023 | |
| elotuzumab | Multiple Myeloma | Anti-CD38/SLAMF7 | β | |
| telisotuzumab vedotin | Lung Cancer | ADC | β | |
| encorafenib + cetuximab | Colorectal Cancer | BRAF/MEK | β | |
| fam-trastuzumab deruxtecan-nxki (t-dxd) | Breast Cancer | ADC | 2019 | |
| trastuzumab deruxtecan | Breast Cancer β’ Gastric Cancer | ADC | β | |
| fam-trastuzumab deruxtecan | Lung Cancer | ADC | β | |
| ensartinib | Lung Cancer | ALK Inhibitor | β | |
| epcoritamab | Non Hodgkins Lymphoma | Bispecific | 2023 | |
| cetuximab | Colorectal Cancer β’ Head Neck Cancer | HER2/EGFR Targeted | β | |
| vismodegib | Basal Cell Carcinoma | Other | β | |
| apalutamide | Prostate Cancer | Hormonal (Prostate) | β | |
| edp-m | Adrenocortical Carcinoma | Chemotherapy | 1970 | |
| 5-fu + leucovorin + irinotecan + oxaliplatin | Pancreatic Cancer | Chemotherapy | β | |
| tivozanib | Kidney Cancer | VEGF/TKI | 2021 | |
| fruquintinib | Colorectal Cancer | VEGF/TKI | 2023 | |
| obinutuzumab | Chronic Lymphocytic Leukemia β’ Follicular Lymphoma | Anti-CD20 | β | |
| afatinib | Lung Cancer | EGFR Inhibitor | β | |
| imatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2001 | |
| carmustine implant | Brain Cancer | Chemotherapy | 1996 | |
| imatinib | Chordoma | BCR-ABL TKI | β | |
| imatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| eribulin | Sarcoma | Chemotherapy | β | |
| trastuzumab | Breast Cancer β’ Esophageal Cancer β’ Gastric Cancer | HER2/EGFR Targeted | 1998 | |
| zongertinib | Lung Cancer | HER2/EGFR Targeted | β | |
| palbociclib | Breast Cancer | CDK4/6 Inhibitor | 2015 | |
| taletrectinib | Lung Cancer | NTRK/ROS1 | β | |
| ponatinib | Acute Lymphoblastic Leukemia | BCR-ABL TKI | 2012 | |
| enasidenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2017 | |
| ibrutinib | Chronic Lymphocytic Leukemia β’ Mantle Cell Lymphoma β’ Waldenstrom Macroglobulinemia | BTK Inhibitor | β | |
| tarlatamab-dlle | Lung Cancer β’ Small Cell Lung Cancer | Bispecific | β | |
| durvalumab | Biliary Tract Cancer β’ Lung Cancer β’ Small Cell Lung Cancer | Checkpoint Inhibitor | β | |
| durvalumab + tremelimumab-actl | Liver Cancer | Checkpoint Inhibitor | 2022 | |
| talimogene laherparepvec (t-vec) | Melanoma | Immunotherapy (Other) | 2015 | |
| axitinib | Kidney Cancer | VEGF/TKI | β | |
| gefitinib | Lung Cancer | EGFR Inhibitor | β | |
| inavolisib | Breast Cancer | PI3K/AKT | 2024 | |
| pirtobrutinib | Chronic Lymphocytic Leukemia β’ Mantle Cell Lymphoma | BTK Inhibitor | 2023 | |
| dostarlimab | Endometrial Cancer | Checkpoint Inhibitor | β | |
| cabazitaxel | Prostate Cancer | Chemotherapy | β | |
| ado-trastuzumab emtansine (t-dm1) | Breast Cancer | ADC | 2013 | |
| pembrolizumab | Anal Cancer β’ Bladder Cancer β’ Breast Cancer β’ Cervical Cancer β’ Colorectal Cancer β’ Cutaneous Squamous Cell β’ Endometrial Cancer β’ Esophageal Cancer β’ Gastric Cancer β’ Head Neck Cancer β’ Hodgkins Lymphoma β’ Liver Cancer β’ Lung Cancer β’ Melanoma β’ Merkel Cell Carcinoma β’ Penile Cancer β’ Small Bowel Cancer β’ Uveal Melanoma β’ Vulvar Cancer | Checkpoint Inhibitor | β | |
| pembrolizumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | β | |
| pembrolizumab + lenvatinib | Kidney Cancer | Checkpoint Inhibitor | 2021 | |
| tebentafusp | Uveal Melanoma | Bispecific | β | |
| ribociclib | Breast Cancer | CDK4/6 Inhibitor | 2017 | |
| adagrasib | Lung Cancer | KRAS Inhibitor | β | |
| tisagenlecleucel | Acute Lymphoblastic Leukemia β’ Non Hodgkins Lymphoma | Cell Therapy | β | |
| carfilzomib | Multiple Myeloma | Proteasome Inhibitor | β | |
| lazertinib | Lung Cancer | EGFR Inhibitor | β | |
| lenvatinib + pembrolizumab | Endometrial Cancer | Checkpoint Inhibitor | β | |
| lenvatinib | Liver Cancer β’ Thyroid Cancer | VEGF/TKI | 2018 | |
| cladribine | Hairy Cell Leukemia | Chemotherapy | β | |
| cemiplimab | Basal Cell Carcinoma β’ Cutaneous Squamous Cell | Checkpoint Inhibitor | β | |
| cemiplimab-rwlc | Lung Cancer | Checkpoint Inhibitor | β | |
| trifluridine/tipiracil | Colorectal Cancer | Other | 2017 | |
| toripalimab | Nasopharyngeal Carcinoma | Checkpoint Inhibitor | β | |
| lorlatinib | Lung Cancer | ALK Inhibitor | β | |
| sotorasib | Lung Cancer | KRAS Inhibitor | β | |
| moxetumomab pasudotox | Hairy Cell Leukemia | Monoclonal Antibody | β | |
| mosunetuzumab-axgb | Follicular Lymphoma β’ Non Hodgkins Lymphoma | Bispecific | 2022 | |
| lutetium lu 177 dotatate | Neuroendocrine Tumors | Radiopharmaceutical | β | |
| olaparib | Ovarian Cancer β’ Pancreatic Cancer β’ Prostate Cancer | PARP Inhibitor | β | |
| mitotane | Adrenocortical Carcinoma | Chemotherapy | 1970 | |
| futibatinib | Biliary Tract Cancer | Kinase Inhibitor | 2022 | |
| rituximab | Follicular Lymphoma | Anti-CD20 | β | |
| methotrexate + doxorubicin + cisplatin | Osteosarcoma | Chemotherapy | β | |
| margetuximab-cmkb | Breast Cancer | HER2/EGFR Targeted | 2020 | |
| trametinib | Melanoma | BRAF/MEK | β | |
| mifamurtide | Osteosarcoma | Other | β | |
| tafasitamab | Non Hodgkins Lymphoma | Anti-CD20 | β | |
| nivolumab | Kidney Cancer | Checkpoint Inhibitor | β | |
| gemtuzumab ozogamicin | Acute Myeloid Leukemia | ADC | 2017 | |
| nab-paclitaxel + gemcitabine | Pancreatic Cancer | Chemotherapy | β | |
| neratinib | Breast Cancer | HER2/EGFR Targeted | 2017 | |
| sorafenib | Kidney Cancer β’ Liver Cancer β’ Thyroid Cancer | VEGF/TKI | β | |
| ixazomib | Multiple Myeloma | Proteasome Inhibitor | β | |
| pentostatin | Hairy Cell Leukemia | Chemotherapy | β | |
| nivolumab + ipilimumab | Kidney Cancer β’ Mesothelioma | Checkpoint Inhibitor | β | |
| darolutamide | Prostate Cancer | Hormonal (Prostate) | 2013 | |
| sonidegib | Basal Cell Carcinoma | Other | β | |
| irinotecan liposome injection | Pancreatic Cancer | Chemotherapy | β | |
| azacitidine (oral) | Acute Myeloid Leukemia | Chemotherapy | 2020 | |
| nivolumab | Anal Cancer β’ Colorectal Cancer β’ Esophageal Cancer β’ Gastric Cancer β’ Head Neck Cancer β’ Hodgkins Lymphoma β’ Lung Cancer β’ Melanoma | Checkpoint Inhibitor | β | |
| nivolumab + cabozantinib | Kidney Cancer | Checkpoint Inhibitor | 2021 | |
| nivolumab + ipilimumab | Kidney Cancer β’ Melanoma β’ Mesothelioma | Checkpoint Inhibitor | β | |
| nivolumab + relatlimab-rmbw | Melanoma | Checkpoint Inhibitor | 2022 | |
| tumor treating fields (ttfields) | Brain Cancer | Other | 2015 | |
| relugolix | Prostate Cancer | Hormonal (Prostate) | 2020 | |
| elacestrant | Breast Cancer | Endocrine (SERD) | 2023 | |
| folfox | Small Bowel Cancer | Chemotherapy | β | |
| paclitaxel | Kaposi Sarcoma | Chemotherapy | β | |
| enfortumab vedotin-ejfv | Bladder Cancer | ADC | β | |
| enfortumab vedotin | Bladder Cancer | ADC | β | |
| pemigatinib | Biliary Tract Cancer | Kinase Inhibitor | 2020 | |
| pembrolizumab + axitinib | Kidney Cancer | Checkpoint Inhibitor | β | |
| pertuzumab | Breast Cancer | Monoclonal Antibody | 2012 | |
| alpelisib | Breast Cancer | PI3K/AKT | 2019 | |
| lutetium lu 177 vipivotide tetraxetan | Prostate Cancer | Radiopharmaceutical | 2013 | |
| polatuzumab vedotin | Non Hodgkins Lymphoma | ADC | 2019 | |
| pomalidomide | Multiple Myeloma | IMiD | β | |
| necitumumab | Lung Cancer | HER2/EGFR Targeted | β | |
| mogamulizumab | Mycosis Fungoides | Monoclonal Antibody | β | |
| sipuleucel-t | Prostate Cancer | Cell Therapy | β | |
| repotrectinib | Lung Cancer | NTRK/ROS1 | β | |
| selpercatinib | Lung Cancer β’ Thyroid Cancer | RET/Multi-Kinase | 2020 | |
| lenalidomide | Follicular Lymphoma β’ Multiple Myeloma | IMiD | 2019 | |
| revumenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2024 | |
| olutasidenib | Acute Myeloid Leukemia | Epigenetic/IDH/Other Targeted | 2022 | |
| rituximab | Non Hodgkins Lymphoma | Anti-CD20 | β | |
| entrectinib | Lung Cancer | NTRK/ROS1 | β | |
| rucaparib | Ovarian Cancer β’ Prostate Cancer | PARP Inhibitor | β | |
| amivantamab-vmjw | Lung Cancer | Bispecific | β | |
| midostaurin | Acute Myeloid Leukemia | Other | 2017 | |
| isatuximab | Multiple Myeloma | Anti-CD38/SLAMF7 | β | |
| lanreotide | Neuroendocrine Tumors | Other | β | |
| dasatinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| regorafenib | Colorectal Cancer β’ Liver Cancer | VEGF/TKI | 2017 | |
| sunitinib | Kidney Cancer β’ Neuroendocrine Tumors | VEGF/TKI | β | |
| capmatinib | Lung Cancer | VEGF/TKI | β | |
| dabrafenib | Melanoma | BRAF/MEK | β | |
| dabrafenib + trametinib | Lung Cancer β’ Thyroid Cancer | BRAF/MEK | β | |
| osimertinib | Lung Cancer | EGFR Inhibitor | β | |
| talquetamab-tgvs | Multiple Myeloma | Bispecific | 2023 | |
| talazoparib | Prostate Cancer | PARP Inhibitor | 2023 | |
| erlotinib | Lung Cancer | EGFR Inhibitor | β | |
| nilotinib | Chronic Myeloid Leukemia | BCR-ABL TKI | 2010 | |
| tazemetostat | Follicular Lymphoma β’ Sarcoma | Epigenetic/IDH/Other Targeted | β | |
| brexucabtagene autoleucel | Acute Lymphoblastic Leukemia β’ Mantle Cell Lymphoma | Cell Therapy | 2021 | |
| atezolizumab | Bladder Cancer β’ Lung Cancer β’ Small Cell Lung Cancer | Checkpoint Inhibitor | β | |
| atezolizumab + bevacizumab | Liver Cancer | Checkpoint Inhibitor | 2020 | |
| teclistamab-cqyv | Multiple Myeloma | Bispecific | 2023 | |
| temozolomide | Brain Cancer | Chemotherapy | β | |
| temozolomide | Brain Cancer | Chemotherapy | 2005 | |
| tepotinib | Lung Cancer | VEGF/TKI | β | |
| ivosidenib | Acute Myeloid Leukemia β’ Biliary Tract Cancer | Epigenetic/IDH/Other Targeted | 2018 | |
| standard chemotherapy | Penile Cancer | Other | β | |
| tisotumab vedotin | Cervical Cancer | ADC | β | |
| topotecan | Small Cell Lung Cancer | Chemotherapy | β | |
| sacituzumab govitecan-hziy | Bladder Cancer β’ Breast Cancer | ADC | β | |
| sacituzumab govitecan | Breast Cancer | ADC | β | |
| capivasertib | Breast Cancer | PI3K/AKT | 2023 | |
| tucatinib | Breast Cancer | HER2/EGFR Targeted | β | |
| tucatinib + trastuzumab | Colorectal Cancer | HER2/EGFR Targeted | 2023 | |
| lapatinib | Breast Cancer | HER2/EGFR Targeted | 2007 | |
| vincristine + doxorubicin + cyclophosphamide | Ewing Sarcoma | Chemotherapy | β | |
| panitumumab | Colorectal Cancer | HER2/EGFR Targeted | β | |
| bortezomib | Mantle Cell Lymphoma β’ Multiple Myeloma | Proteasome Inhibitor | β | |
| venetoclax | Acute Myeloid Leukemia β’ Chronic Lymphocytic Leukemia | BCL-2 Inhibitor | 2018 | |
| abemaciclib | Breast Cancer | CDK4/6 Inhibitor | 2017 | |
| larotrectinib | Lung Cancer | NTRK/ROS1 | β | |
| dacomitinib | Lung Cancer | EGFR Inhibitor | β | |
| vorasidenib | Brain Cancer | Epigenetic/IDH/Other Targeted | 2024 | |
| pazopanib | Sarcoma | VEGF/TKI | β | |
| zolbetuximab-clzb | Gastric Cancer | HER2/EGFR Targeted | 2024 | |
| daunorubicin/cytarabine liposome | Acute Myeloid Leukemia | Chemotherapy | 2017 | |
| belzutifan | Kidney Cancer | Epigenetic/IDH/Other Targeted | 2021 | |
| crizotinib | Lung Cancer | ALK Inhibitor | β | |
| radium ra 223 dichloride | Prostate Cancer | Radiopharmaceutical | 2013 | |
| gilteritinib | Acute Myeloid Leukemia | Kinase Inhibitor | 2018 | |
| selinexor | Multiple Myeloma | XPO1 Inhibitor | 2019 | |
| enzalutamide | Prostate Cancer | Hormonal (Prostate) | β | |
| ipilimumab | Melanoma | Checkpoint Inhibitor | β | |
| axicabtagene ciloleucel (axi-cel) | Non Hodgkins Lymphoma | Cell Therapy | 2017 | |
| axicabtagene ciloleucel | Non Hodgkins Lymphoma | Cell Therapy | β | |
| trabectedin | Sarcoma | Chemotherapy | β | |
| ziv-aflibercept | Colorectal Cancer | VEGF/TKI | β | |
| sunvozertinib | Lung Cancer | EGFR Inhibitor | β | |
| niraparib | Ovarian Cancer | PARP Inhibitor | β | |
| vemurafenib | Melanoma | BRAF/MEK | β | |
| lurbinectedin | Ewing Sarcoma β’ Lung Cancer β’ Small Cell Lung Cancer | Chemotherapy | β | |
| ceritinib | Lung Cancer | ALK Inhibitor | β | |
| loncastuximab tesirine-lpyl | Non Hodgkins Lymphoma | ADC | 2021 | |
| retifanlimab | Merkel Cell Carcinoma | Checkpoint Inhibitor | β | |
| abiraterone acetate | Prostate Cancer | Hormonal (Prostate) | β | |
| abiraterone | Prostate Cancer | Hormonal (Prostate) | β | |
| Iclusig | ponatinib | BCR-ABL TKI | Chronic Myeloid Leukemia | 2012 |
| Scemblix | asciminib | BCR-ABL TKI | Chronic Myeloid Leukemia | 2021 |
| Retevmo | selpercatinib | RET/Multi-Kinase | Thyroid Cancer | 2020 |
| Caprelsa | vandetanib | RET/Multi-Kinase | Thyroid Cancer | 2011 |
| Gavreto | pralsetinib | RET/Multi-Kinase | Thyroid Cancer | 2020 |
| Tafinlar + Mekinist | dabrafenib + trametinib | BRAF/MEK | Thyroid Cancer | 2018 |
| Yescarta | axicabtagene ciloleucel | Cell Therapy | Follicular Lymphoma | 2021 |
| Istodax | romidepsin | Epigenetic/IDH/Other Targeted | Mycosis Fungoides | 2009 |
| Zolinza | vorinostat | Epigenetic/IDH/Other Targeted | Mycosis Fungoides | 2006 |
| Enhertu | fam-trastuzumab deruxtecan | ADC | Esophageal Cancer | 2021 |
| Cyramza | ramucirumab | Monoclonal Antibody | Esophageal Cancer | 2014 |
| Xermelo | telotristat ethyl | Other | Neuroendocrine Tumors | 2017 |
| Tazverik | tazemetostat | Epigenetic/IDH/Other Targeted | Sarcoma | 2020 |
| Clolar | clofarabine | Chemotherapy | Acute Lymphoblastic Leukemia | 2004 |
| Rylaze | asparaginase erwinia chrysanthemi | Chemotherapy | Acute Lymphoblastic Leukemia | 2021 |
| Rituxan | rituximab | Anti-CD20 | Waldenstrom Macroglobulinemia | 1997 |
| copanlisib | Follicular Lymphoma | PI3K Inhibitor | 2017 | |
| mirvetuximab soravtansine | Ovarian Cancer | ADC (FRΞ±-targeted) | 2025 | |
| repotrectinib | Lung Cancer | ROS1/NTRK Inhibitor | 2023 | |
| avutometinib | Ovarian Cancer | RAF/MEK Inhibitor | 2025 | |
| belantamab mafodotin | Multiple Myeloma | ADC (BCMA-targeted) | 2020 | |
| encorafenib | Melanoma | BRAF Inhibitor | 2018 | |
| lutetium PSMA-617 | Prostate Cancer | Radiopharmaceutical | 2024 | |
| lomustine | Brain Cancer | Alkylating Agent | 1976 | |
| cabozantinib | Thyroid Cancer | Multi-Kinase Inhibitor | 2012 | |
| trilaciclib | Small Cell Lung Cancer | CDK4/6 Inhibitor | 2021 | |
| doxorubicin liposomal | Ovarian Cancer | Anthracycline (Liposomal) | 1995 | |
| tagraxofusp | Non Hodgkins Lymphoma | CD123-directed Cytotoxin | 2018 | |
| pirtobrutinib | Mantle Cell Lymphoma | BTK Inhibitor (Non-covalent) | 2023 | |
| panobinostat | Multiple Myeloma | HDAC Inhibitor | 2015 | |
| obinutuzumab | Chronic Lymphocytic Leukemia | Anti-CD20 Monoclonal Antibody | 2013 | |
| carmustine implant | Brain Cancer | Alkylating Agent (Implant) | 1996 | |
| mirdametinib | Colorectal Cancer | MEK Inhibitor | 2025 | |
| relugolix | Prostate Cancer | GnRH Receptor Antagonist | 2025 | |
| quizartinib | Acute Myeloid Leukemia | FLT3 Inhibitor | 2023 | |
| leuprolide acetate | Prostate Cancer | GnRH Agonist | 2024 | |
| lazertinib | Lung Cancer | EGFR Inhibitor (3rd Gen) | 2025 | |
| lorlatinib | Lung Cancer | ALK/ROS1 Inhibitor | 2024 | |
| decitabine + cedazuridine | Acute Myeloid Leukemia | Hypomethylating Agent | 2020 | |
| eflornithine | Multiple | ODC Inhibitor | 2023 | |
| ruxolitinib | Non Hodgkins Lymphoma | JAK1/JAK2 Inhibitor | 2011 | |
| ziftomenib | Acute Myeloid Leukemia | Menin Inhibitor | 2025 | |
| selumetinib | Multiple | MEK Inhibitor | 2020 | |
| lurbinectedin | Small Cell Lung Cancer | RNA Pol II Inhibitor | 2020 | |
| odronextamab | Non Hodgkins Lymphoma | CD20ΓCD3 Bispecific | 2025 | |
| asciminib | Chronic Myeloid Leukemia | BCR-ABL1 STAMP Inhibitor | 2024 | |
| tafasitamab | Non Hodgkins Lymphoma | Anti-CD19 Monoclonal Antibody | 2020 | |
| tovorafenib | Brain Cancer | RAF Inhibitor | 2024 | |
| pemigatinib | Biliary Tract Cancer | FGFR Inhibitor | 2020 | |
| melphalan flufenamide | Multiple Myeloma | Alkylating Agent | 2021 | |
| rituximab | Non Hodgkins Lymphoma | Anti-CD20 Monoclonal Antibody | 1997 | |
| ramucirumab | Mesothelioma | VEGFR2 Inhibitor | 2023 | |
| omacetaxine mepesuccinate | Chronic Myeloid Leukemia | Protein Synthesis Inhibitor | 2012 | |
| bexarotene | Mycosis Fungoides | RXR Agonist | 1999 | |
| paclitaxel | Breast Cancer | Taxane Chemotherapy | 1992 | |
| tebentafusp-tebn | Uveal Melanoma | ImmTAC / TCR Bispecific | 2022 | |
| dinutuximab | Multiple | Anti-GD2 Monoclonal Antibody | 2015 | |
| venetoclax | Chronic Lymphocytic Leukemia | BCL-2 Inhibitor | 2016 | |
| pacritinib | Non Hodgkins Lymphoma | JAK2/FLT3 Inhibitor | 2022 | |
| oportuzumab monatox | Bladder Cancer | EpCAM Immunotoxin | 2025 | |
| idelalisib | Chronic Lymphocytic Leukemia | PI3Kd Inhibitor | 2014 |